GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235
GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical...
35Pharma
GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235
GlaxoSmithKline (GSK, NYSE: GSK) announced a definitive agreement to acquire 35Pharma Inc., a Canada‑based clinical‑stage biopharmaceutical...